Summary

Noninvasive massive parallel sequencing of circulating cell-free DNA allows the identification of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage NSHL. This discovery may facilitate the development of predictive biomarkers and monitoring early disease response to therapy. These issues will be investigated in the context of clinical trials.